The Polish Intestinal Failure Centres’ consensus on the use of teduglutide for the treatment of short bowel syndrome
| Autor: | Stanislaw Klek, Marek Kunecki, Krystyna Urbanowicz, Jacek Sobocki, Katarzyna Karwowska, Konrad Matysiak |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Short Bowel Syndrome
0301 basic medicine medicine.medical_specialty Endocrinology Diabetes and Metabolism Teduglutide 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Gastrointestinal Agents Intestinal failure medicine Humans In patient Clinical efficacy Intensive care medicine Reimbursement 030109 nutrition & dietetics Nutrition and Dietetics business.industry Short bowel syndrome medicine.disease Treatment Outcome Parenteral nutrition chemistry Inclusion and exclusion criteria 030211 gastroenterology & hepatology Poland Peptides business |
| Zdroj: | Nutrition. 38:28-33 |
| ISSN: | 0899-9007 |
| DOI: | 10.1016/j.nut.2016.12.022 |
| Popis: | Objective Teduglutide is an active, glucagon-like peptide (GLP)-2 analog with proven clinical efficacy regarding intestinal adaptation in patients with short bowel syndrome (SBS). There are two factors that preclude its reimbursement, and thereby, its availability: its cost (reaching ∼$300,000/y)—which significantly exceeds the cost of home parenteral nutrition (HPN) in most countries—and the lack of clear guidelines. The aim of this study was to create evidence-based working criteria for the use of teduglutide that could be used in clinical settings. Methods Experts from the Polish Network of Intestinal Failure Centers analyzed available research and considered experience on the topic of HPN and intestinal failure to create guidelines. Results Experts agreed that there are two groups of HPN patients who can benefit from therapy with a GLP-2 analog: those with a good prognosis (in whom complete weaning from HPN may be possible) and those with a poor prognosis (the therapy would be lifesaving). Patient criteria comprise the following: inclusion and exclusion criteria, parameters that can be used for monitoring, outcome measures, and the rationale for the termination of the treatment. Conclusions It was possible to describe inclusion criteria for both patient groups that justify the use of teduglutide from medical and economic perspectives. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect